Novo Drug Patent Portfolio

Novo's Family Patents

Title	Lead Sponsor	Collaborators	Status	Phases

A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes	Novo Nordisk A/S	NA	RECRUITING (Sep, 2024)	PHASE3
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Finland, as Part of Local Clinical Practice	Novo Nordisk A/S	NA	COMPLETED (Sep, 2024)
Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)	Novo Nordisk A/S	NA	ACTIVE NOT RECRUITING (Sep, 2024)	PHASE3
A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy	Novo Nordisk A/S	NA	ENROLLING BY INVITATION (Oct, 2023)
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People	Novo Nordisk A/S	NA	COMPLETED (Jun, 2023)	PHASE1
Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes	Novo Nordisk A/S	NA	COMPLETED (Jul, 2022)	PHASE3
A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes	Novo Nordisk A/S	NA	COMPLETED (Aug, 2018)	PHASE1

Drugs Generating Over $1 Billion in Annual Revenue

Explore the top-performing drugs that dominate the pharmaceutical industry

View List

NCE-1 Patent Expiry in the Next 1 Year

Identify opportunities as new chemical entity (NCE-1) patents approach expiry

View List

Recently Granted Patents in EP

Find the opportunity to file Oppositions

View List

Generic brands are quickly moving to capitalize on the expiration of the semaglutide patent, with long-term success expected for 5-6 key players.

13 Mar, 2026

Central Drugs Standard Control Organisation (CDSCO) Prohibits Advertising of Weight-Loss Medications

12 Mar, 2026

Could Changes in Policy Boost Demand for Eli Lilly's GLP-1 Medications? - TradingView

12 Mar, 2026

Regulatory authorities in India issue a warning regarding aggressive marketing of weight-loss medications.

12 Mar, 2026